IGFBP-4: a promising biomarker for lung cancer
Abstract
Background: Insulin-like growth factor binding protein-4 (IGFBP-4), a member of the insulin like growth factor (IGF) family, transports and regulates the activity of IGFs. Pregnancy associated protein-A (PAPP-A) has proteolytic activity towards IGFBP-4 and both have been associated with a variety of cancers, including lung. We aimed to evaluate the utility of IGFBP-4 and PAPP-A as potential biomarkers in lung cancer.
Materials and Methods: Eighty-three volunteers, including 60 patients with lung cancer and 23 healthy individuals, were included. Patients with lung cancer were selected based on treatment status, histological subgroup, and stage of the disease. Enzyme-linked immunosorbent assays were used to assess serum levels of IGFBP-4 and PAPP-A, whereas IGF-1 levels were measured using a chemiluminescent immunometric assay.
Results: Serum IGFBP-4 levels in all patient groups, regardless of treatment status and histological differences, were significantly higher than those in the control group (p < 0.005). However, serum PAPP-A levels in the untreated patient group were found to be higher than those in the control group, and this difference was not statistically significant (p = 0.086).
Conclusion: Serum PAPP-A and IGFBP-4 levels are elevated in lung cancer. However, IGFBP-4 may have a better potential than PAPP-A as a lung cancer biomarker.
References
[2] Mao, Yousheng, et al. Epidemiology of lung cancer. Surgical Oncology Clinics, 2016, 25.3: 439-445.
[3] Toyoda, Y., et al. Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography. British journal of cancer, 2008, 98.10: 1602.
[4] Greenberg, Alissa K.; LEE, M. Sung. Biomarkers for lung cancer: clinical uses. Current opinion in pulmonary medicine, 2007, 13.4: 249-255.
[5] Shibayama, Takuo, et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung cancer, 2001, 32.1: 61-69.
[6] Molina, R., et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Tumor biology, 2003, 24.4: 209-218.
[7] Cho, William Chi-Shing. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed Pharmacother 2007; 61(9):515-519.
[8] Planque, Chris, et al. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Molecular & cellular proteomics, 2009, 8.12: 2746-2758.
[9] Y Song, Shanshan; YU, Hong; LI, Qi. Genome survey and characterization of reproduction-related genes in the Pacific oyster. Invertebrate reproductIon & development, 2017, 61.2: 97-109.
[10] Oxvıg, Claus. The role of PAPP-A in the IGF system: location, location, location. Journal of cell communication and signaling, 2015, 9.2: 177-187.
[11] Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 198; 140:19-24.
[12] Shimasaki, Shunichi; LING, Nicholas. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1,-2,-3,-4,-5 and-6). Progress in growth factor research, 1991, 3.4: 243-266.
[13] Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92.18:1472-1489.
[14] Xiao Y, Zhu S, Yin W, Liu X, Hu Y. IGFBP‑4 expression is adversely associated with lung cancer prognosis. Oncology letters 2017; 14(6):6876-6880.
[15] Mikkelsen JH, Resch ZT, Kalra B, Savjani G, Kumar A, Conover CA, Oxvig C. Indirect targeting of IGF receptor signaling in vivo by substrate-selective inhibition of PAPP-A proteolytic activity. Oncotarget 2014; 5(4):1014–1025.
[16] Bulut I, Coskun A, Ciftci A, Cetinkaya E, Altiay G, Caglar T, Gulcan E. Relationship between pregnancy-associated plasma protein-A and lung cancer. Am J Med Sci 2009; 337:241–244.
[17] Pan H, Hanada S, Zhao J, Mao L, Ma MZQ. Protein secretion is required for pregnancy-associated plasma protein-A to promote lung cancer growth in vivo. PloS one 2012; 7(11):48799.
[18] Goldstraw, Peter, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. Journal of Thoracic Oncology, 2016, 11.1: 39-51.
[19] Wang Z, Wang Z, Liang Z, Liu J, Shi W, Bai P, Lin X, Magaye R and Zhao J: Expression and clinical significance of IGF-1, IGFBP-3, and IGFBP-7 in serum and lung cancer tissues from patients with non-small cell lung cancer. Onco Targets Ther 6: 1437-1444, 2013.
[20] Lee DY, Kim SJ and Lee YC: Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci 14: 401-404, 1999.
[21] Tas, Faruk, et al. Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer. Biomedical reports, 2016, 4.5: 609-614.
[22] UnsaL E, Köksal D, Yurdakul AS, Atikcan S and Cinaz P: Analysis of insulin like growth factor 1 and insulin like growth factor binding protein 3 levels in bronchoalveolar lavage uid and serum of patients with lung cancer. Respir Med 99: 559-565, 2005.
[23] Izycki T, Chyczewska E, Naumnik W, Ossolinska M. Serum levels of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy. Oncol Res Featuring Preclinical and Clinical Cancer Therapeutics 2006; 16(1):49-54.
[24] KasprzaK, Aldona, et al. Insulin-like growth factor (IGF) axis in cancerogenesis. Mutation Research/Reviews in Mutation Research, 2017, 772: 78-104.
[25] Moreno MJ, Ball M, Andrade MF, McDermid A, Stanimirovic DB. Insulin‐like growth factor binding protein‐4 (IGFBP‐4) is a novel anti‐angiogenic and anti‐tumorigenic mediator secreted by dibutyryl cyclic AMP (dB‐cAMP)‐differentiated glioblastoma cells. Glia 2006; 53(8):845-857.
[26] Mazerbourg S, Callebaut I, Zapf J, Mohan S, Overgaard M, Monget P. Up date on IGFBP-4: regulation of IGFBP-4 levels and functions, in vitro and in vivo. Growth Horm IGF Res 2004; 14(2):71-84.
[27] Sato, Hanako, et al. Insulin‐like growth factor binding protein‐4 gene silencing in lung adenocarcinomas. Pathology international, 2011, 61.1: 19-27.
[28] Moreno, María J., et al. IGFBP-4 anti-angiogenic and anti-tumorigenic effects are associated with anti-cathepsin B activity. Neoplasia (New York, NY), 2013, 15.5: 554.
[29] Hermani, Alexander, et al. Insulin-like growth factor binding protein-4 and-5 modulate ligand-dependent estrogen receptor-α activation in breast cancer cells in an IGF-independent manner. Cellular signalling, 2013, 25.6: 1395-1402.
[30] Diehl, Daniela, et al. Insulin-like growth factor (IGF)-binding protein-4 inhibits colony formation of colorectal cancer cells by IGF-independent mechanisms. Cancer research, 2004, 64.5: 1600-1603.
[31] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5):646.
[32] Yang, Binyao, et al. Overexpression of lncRNA IGFBP4–1 reprograms energy metabolism to promote lung cancer progression. Molecular cancer, 2017, 16.1: 154.
[33] Z Kjaer-Sorensen, Kasper, et al. Pregnancy-associated plasma protein A (PAPP-A) modulates the early developmental rate in zebrafish independently of its proteolytic activity. Journal of Biological Chemistry, 2013, 288.14: 9982-9992.
[34] Salim H, Arvanitis A, de Petris L, Kanter L, Haag P, Zovko A, Ozata DM, Lui WO, Lundholm L, Zhivotovsky B, Lewenson R, Viktorsson K. miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression. Genes Chromosomes Cancer 2013; 52(10):895–911.
[35] Espelund US, Bjerre M, Hjortebjerg R, Rasmussen TR, Lundby A, Hoeflich A, Folkersen BH, Oxvig C, Frystyk J. IGF bioactivity, Stanniocalcin-2, PAPP-A, and IGFBP-4 in pleural fluid and serum from patients with pulmonary disease. J Clin Endocrinol Metab 2017; 102(9):3526–3534.
[36] Kloverpris S, Mikkelsen JH, Pedersen JH, Jepsen MR, Laursen LS, Petersen SV Oxvig C. Stanniocalcin-1 potently inhibits the proteolytic activity of the metalloproteinase pregnancy-associated plasma protein-A. J Biol Chem 2015; 290(36):21915–21924.
[37] Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-1 axis in ageing and longevity. Nat. Rev. Endocrinol. 2013; 9(6):366
Copyright (c) 2020 irem nur Savaş, Akın Öztürk, Murat Kavas, İsmet Bulut, Sümeyye Alparslan, Selma Aydoğan Eroğlu, Cansel Atinkaya Baytemir, Murat Kolay, Abdurrahman Coşkun
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.